Flexibility in screening paradigm and sample type

BD Onclarity™ HPV Assay empowers you to meet the needs of the rapidly changing cervical screening landscape and adapt to evolving guidelines.

Flexibility in screening paradigm

BD Onclarity™ HPV Assay is CE-marked, FDA-approved for primary screening and fulfils the Meijer criteria, offering flexibility to adapt to evolving guidelines.^1,2

 Flexibility to choose sample type

The BD Onclarity™ HPV Assay uses a harmonised workflow regardless of the specimen type and is also validated for HPV primary screening on self-collected samples.¹

BD Onclarity™ HPV Assay is validated for use with:¹

• Liquid-based cytology specimens
• Cervical brush specimens
• Self-collected vaginal specimens

BD Onclarity™ HPV Assay is the only HPV test providing extended genotyping both CE-marked and FDA-approved for HPV primary screening, triage of ASC-US cytology and co-testing.^4,5

ASC-US, atypical squamous cells of undetermined significance; FDA, Food and Drug Administration; HPV, human papillomavirus.

1. BD Onclarity™ HPV Assay Package Insert [8089899].
2. BD Onclarity™ HPV Assay US Package Insert [8089894].
3. Meijer CJLM et al. Int J Cancer. 2009;124(3):516–20.
4. Arbyn M et al. Clin Microbiol Infect. 2021;27(8):1083–95.
5. Salazar KL et al. J Am Soc Cytopathol. 2019;8(5):284–92.